Swiss Federal Institute of Technology

Originator Org.

Gastro-Enteropancreatic Neuroendocrine Tumor [+3]

Active Indication

Inactive Indication

Small Cell Lung Cancer

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

R-[11C]-Me-NB1

Target

GluN2B

Mechanism

GluN2B modulators [+1]

Active Org.

Originator Org.

Neurodegenerative Diseases

Active Indication

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

161Tb-DOTATATE

Target-

Mechanism-

Active Org.

Originator Org.

Active Indication

Neoplasms

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

295

Clinical Trials associated with Swiss Federal Institute of Technology

NCT06822062

/ Not yet recruitingNot ApplicableIIT

The Effect of Chitin and Ascorbic Acid on Dietary Iron Absorption from Tenebrio Molitor Larvae in Young Women.

Iron is involved in many vital metabolic processes such as oxygen transport, electron transport in cells, DNA synthesis and repair, and muscle metabolism. However, iron deficiency and iron deficiency anemia continue to affect many people, particularly preschool children (<5 years), adolescents, and pregnant and non-pregnant women of childbearing age. Iron deficiency is characterized by a lack of total iron stores in the body, which is mainly caused by insufficient dietary iron intake, physiologically increased iron requirements, poor intestinal iron absorption, or chronic blood loss. Animal foods are important sources of highly bioavailable iron in the human diet. Meeting human nutritional needs for the rapidly increasing world population while targeting food production within the planetary boundaries will require the identification of sustainable iron sources, such as edible insects. A previous iron absorption study showed that insect iron is absorbed moderately well. The present study will examine if and to which extent chitin, a polysaccharide within the insect biomass, inhibits iron absorption. In addition, the enhancing iron absorption of ascorbic acid on iron absorption from Tenebrio molitor larvae will be studied. This knowledge can support to optimize the composition of an insect-based meal to increase its iron absorption.
To distinguish iron absorption from insect biomass from other sources, insects are labeled with stable iron isotopes (Fe-57, Fe-58, Fe-54) and iron absorption in the blood is measured.

Start Date01 Mar 2025

Sponsor / Collaborator

NCT06816524

/ Not yet recruitingNot ApplicableIIT

The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants with Iron Deficiency

Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.
In this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21/Matrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.

Start Date01 Mar 2025

Sponsor / Collaborator

[+2]

NCT06856291

/ Not yet recruitingNot ApplicableIIT

Treatment Response to Incretin Mimetics in Non-diabetic Obese Patients with and Without Insulin Resistance (TRIM-IR)

Incretin mimetics are widely used pharmacological treatments for weight loss, known for their high efficacy and favorable safety profile. As the most commonly prescribed drug in this class, semaglutide is effective in both diabetic and non-diabetic individuals. However, treatment responses vary significantly, with non-diabetic individuals typically experiencing better weight loss outcomes. Despite this, up to 10% of non-diabetic individuals show little or no response to treatment, and the reasons for this variability remain unclear.
The TRIM-IR study aims to investigate the role of insulin resistance (IR) in weight loss outcomes among non-diabetic obese individuals receiving semaglutide. This single-center, observational study will assess the impact of IR on weight loss, body composition, and adipose tissue function during the first 16 weeks of semaglutide therapy. The study will also explore molecular markers of adipose tissue dysfunction, focusing on the transition from dysfunctional to healthy adipose tissue.
The investigators hypothesize, that individuals with lower IR will experience greater weight loss than those with higher IR, and that the glucose infusion rate (GIR) during hyperinsulinemic euglycemic clamp testing will correlate with weight loss variability. Secondary objectives include comparing changes in fat and lean mass, reductions in visceral fat, and improvements in adipose tissue function before and after 16 weeks of treatment. Exploratory analyses will assess adipocyte subpopulations and their response to insulin sensitivity changes.
A total of 40 participants, equally distributed by gender, will be enrolled to ensure statistical power for detecting clinically relevant differences. The study aims to optimize semaglutide use for personalized obesity treatment and provide insights into the relationship between obesity, insulin resistance, and adipose tissue plasticity, with implications for improving obesity management and cardiovascular health outcomes.

Start Date01 Mar 2025

Sponsor / Collaborator

Ymmunobio and PSI Secure Innosuisse Grant to Advance Radio-pharmaceutical YB-800

100 Clinical Results associated with Swiss Federal Institute of Technology

0 Patents (Medical) associated with Swiss Federal Institute of Technology

46,806

Literatures (Medical) associated with Swiss Federal Institute of Technology

01 Dec 2025·ARCHIVE FOR HISTORY OF EXACT SCIENCES

A clockmaker’s mathematics: a technology-based approach to the mathematical works of Jost Bürgi (1552–1632)

Article

Author: Moosbrugger, Damian

Abstract:

In this article, I propose a new approach to analyze the interrelations between mathematics and technology. It has the potential to contribute methodologically to both the fields of history of mathematics as well as the study of computational technologies in the current context. Based on the conception of mathematics as a contingent human practice, I claim that the practical engagement with technology not only subjects new fields, materials, and problems to mathematical scrutiny but might even shape mathematics from within. To illustrate my approach and corroborate my thesis, I present a historical case study on the mathematical works of the Swiss clock- and instrument-maker Jost Bürgi (1552–1632). Besides being a practicing artisan, he left three mathematical treatises. The advancements in fine metal working at his time, exemplified in clockwork mechanisms and measuring instruments, not only motivated and directed Bürgi’s mathematical inquiries. Instead, I argue that the interaction with these technical apparatuses in practice has shaped the internal structure and workings of his mathematics, that is, its entities, justifications, presentations, proofs, and procedures. The close analysis of some aspects of his oeuvre, especially his notion(s) of the sine, his way of explaining the occurrence of multiple solutions in algebra, and his visual depiction of the bridging of ten in his logarithmic computational tool, reveals a potential integration of the experience and practical knowledge of a clockmaker into mathematics. I therefore make the point that his mathematical writings portray a clockmaker’s mathematics.

01 Jun 2025·ANNALS OF NUCLEAR ENERGY

Adjusting JEFF-3.3 actinide data using a new, dedicated methodology for selecting suited assimilation database parameters

Author: Rochman, Dimitri ; Pelloni, Sandro

A general method is proposed to choose, among several benchmarks, suitable assimilation database parameters to be used in adjustments.All these benchmarks are predetermined keeping in mind specific goals of the data assimilation.The main principle of the novel methodol. is that of excluding groups of strongly cross-correlated computed parameters by estimating their posterior values of χ².The assimilation tries minimizing the mean χ² for the entirety of the considered benchmarks, including those target parameters which are not part of the selected assimilation database.The methodol. currently applied to the JEFF-3.3 library, is demonstrated by adjusting data for ²³⁵U, ²³⁸U, ²³⁹Pu and ²⁴⁰Pu in conjunction with a class of integral parameters (effective multiplication factors) of fast criticalities including the Godiva and Jezebel spheres, for which the effect of varying resonance parameters in the calculations may be largely neglected.The computed mean χ² of 36 values in total, among which seven refer to the assimilation database, is halved, and the variance of the individual χ²-values decreases by a factor of 6 with respect to the prior values.More explicitly, the posterior values of resp. 1.10 and 3.77 for χ² and the variance of the individual χ²-values are much smaller than the corresponding prior values of 2.32 and 22.38, which is significant.As regards the adjustment, for ²³⁵U, it is found that μ and the inelastic scattering cross-section resp. decrease by maximum 3% and 2.6%; ν is uniformly decreased by maximum 0.053% and the fission spectrum is somewhat harder.For ²³⁸U, μ increases by maximum 5.4% and the inelastic scattering cross-section is lowered by 1%.For ²³⁹Pu, ν is uniformly increased by maximum 0.027% and the fission spectrum is slightly softer.For ²⁴⁰Pu, the fission cross-section is decreased by maximum 3.9%.The proposed adjustments are well within the uncertainty limit of one standard deviation for the nuclear data.

01 May 2025·SLEEP MEDICINE

Robotic beds for the treatment of positional obstructive sleep apnea – A randomized cross-over pilot trial

Article

Author: Meszaros, Martina ; Wilhelm, Elisabeth ; Riener, Robert ; Breuss, Alexander ; Schwarz, Esther I ; Kohler, Malcolm

BACKGROUND:

Interventions leading to avoidance of supine position and thus reducing the likelihood of upper airway collapse during sleep are a treatment approach for positional obstructive sleep apnea (POSA). The aim of this randomized cross-over trial was to assess the effect of two actuated beds (trunk-elevation and sideward-tilting) on OSA severity and sleep fragmentation in POSA.

METHODS:

After baseline polysomnography, adult patients with POSA were randomly assigned to two nights of intervention in the intelligent sleep apnea bed ISABel1 and ISABel2. In the case of obstructive apnea or hypopnea, ISABel1 elevated the upper body by 50° and ISABel2 induced a unilateral bed tilt of 40°, with both interventions lasting 10 min. Sustained trunk elevations without sliding down (ISABel1) and position change from supine to non-supine (ISABel2) were defined as successful interventions.

RESULTS:

Six adult men (57 ± 11 years, BMI 28 ± 4 kg/m2, AHI 39 ± 15/h) with POSA were included. Neither trunk elevation (ISABel1) nor side tilt (ISABel2) - approximately 10 interventions per night - significantly reduced apnea-hypopnea index (AHI), whereas trunk elevation showed a tendency to reduce supine AHI. Actuated beds had no effect on sleep efficiency and arousals. Only 13 % of side tilts in ISABel2 resulted in a successful shift to a non-supine position. The time to the next respiratory event after bed movement was longer in the trunk elevating bed than in the side-tilting bed.

CONCLUSION:

Trunk elevating beds decrease supine AHI and both side-tilting and trunk elevating beds increase the time to the next obstructive apnea or hypopnea.

News (Medical) associated with Swiss Federal Institute of Technology

23 Jan 2025

·pipelinereview.com

PRINCETON, NJ, USA I January 23, 2025 I Ymmunobio (YB) is excited to share that they in collaboration with the Paul Scherrer Institute (PSI) have received Innosuisse support to develop innovative radioactive loaded antibodies for the treatment and diagnostic of solid tumors based on YBs proprietary YB-800. The Innosuisse support validates Ymmunobio’s approach to targeted solid tumor therapy using a new and first in class target with a high prevalence in cancer patients. The newly developed antibodies will utilize a linker attached to YB-800, capable of carrying any radioactive isotope for the treatment and diagnostic of solid tumors. Ymmunobio plans to leverage this cutting-edge technology to treat patients with solid tumors who express the new marker. Radiolabeled antibodies will enhance physicians’ ability to diagnose using SPECT imaging while simultaneously targeting solid tumors that evade current therapies, paving the way for more personalized and effective treatment strategies. Dr. Peter Schiemann, Ymmunobio CEO and Chair of the Board says: “The support by Innosuisse validates our novel and first in class approach to solid tumor treatment and improving patient outcomes through advanced diagnostic and therapeutic solutions. We are proud to have received this Innosuisse validation and to have found an exceptional partner to co-develop these new treatment options for patients. Together, YB and PSI are pioneering advances in diagnostics and treatments in oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.” Dr. Martin Behe, project leader at PSI, is excited about project: “Radiolabeled compounds for cancer therapy and diagnosis have attracted significant attention from both physicians and the industry. Several of these radiopharmaceuticals have been successfully tested in clinical trials and are now routinely used in therapies, such as for prostate cancer. We are excited to collaborate with Ymmunobio in developing a radiolabeled antibody to further improve cancer treatment. This project is made possible with the support of Innosuisse.” Ymmunobio is at the forefront of oncology research, focusing on a novel target receptor for the treatment of solid tumors with high unmet need. Currently, in pre-clinical development, Ymmunobio’s research is dedicated to advancing three treatment options for GI cancers, with their innovative platform: SOURCE: Ymmunobio

23 Jan 2025

·www.prnewswire.com

Ymmunobio and PSI Secure Innosuisse Grant to Advance Radio-pharmaceutical YB-800

PRINCETON, N.J., Jan. 23, 2025 /PRNewswire/ -- Ymmunobio (YB) is excited to share that they in collaboration with the Paul Scherrer Institute (PSI) have received Innosuisse support to develop innovative radioactive loaded antibodies for the treatment and diagnostic of solid tumors based on YBs proprietary YB-800. The Innosuisse support validates Ymmunobio's approach to targeted solid tumor therapy using a new and first in class target with a high prevalence in cancer patients. Continue Reading Ymmunobio: Cancer Therapies for Tomorrow & Beyond The newly developed antibodies will utilize a linker attached to YB-800, capable of carrying any radioactive isotope for the treatment and diagnostic of solid tumors. Ymmunobio plans to leverage this cutting-edge technology to treat patients with solid tumors who express the new marker. Radiolabeled antibodies will enhance physicians' ability to diagnose using SPECT imaging while simultaneously targeting solid tumors that evade current therapies, paving the way for more personalized and effective treatment strategies. Dr. Peter Schiemann, Ymmunobio CEO and Chair of the Board says: "The support by Innosuisse validates our novel and first in class approach to solid tumor treatment and improving patient outcomes through advanced diagnostic and therapeutic solutions. We are proud to have received this Innosuisse validation and to have found an exceptional partner to co-develop these new treatment options for patients. Together, YB and PSI are pioneering advances in diagnostics and treatments in oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients." Dr. Martin Behe, project leader at PSI, is excited about project: "Radiolabeled compounds for cancer therapy and diagnosis have attracted significant attention from both physicians and the industry. Several of these radiopharmaceuticals have been successfully tested in clinical trials and are now routinely used in therapies, such as for prostate cancer. We are excited to collaborate with Ymmunobio in developing a radiolabeled antibody to further improve cancer treatment. This project is made possible with the support of Innosuisse." Ymmunobio is at the forefront of oncology research, focusing on a novel target receptor for the treatment of solid tumors with high unmet need. Currently, in pre-clinical development, Ymmunobio's research is dedicated to advancing three treatment options for GI cancers, with their innovative platform: YB-800ADC carrying up to 8 payloads with a linker of the 3rd generation YB-800R1 (therapeutic) and YB-800R2 (diagnostic) antibodies carrying radioactive isotopes in collaboration with PSI YB-800BS, bi-specific antibodies with an aCD3 T-Cell engager. Media Contact: Selena Blackmore [email protected] +41 (0) 76 378 59 30 SOURCE Ymmunobio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

08 Jan 2025

·www.pharmaceutical-technology.com

Chugai and Araris enter $780m ADC research collaboration

Chugai has already overseen the approval of Roche’s Polivy in Japan for lymphoma treatment. Image credit: Shutterstock / Piotr Swat. Chugai Pharmaceutical and Araris Biotech have entered an antibody-drug conjugate (ADC)-focused research collaboration and option-to-license agreement worth up to $780m. Under the deal, Swiss oncology biotech Araris will use its ADC platform to generate ADCs using Chugai-provided antibodies against undisclosed targets supplied by Chugai. Japan-headquartered Chugai will oversee the funding of the research and will oversee development, manufacturing and global commercialisation duties if it decides to license a candidate. Araris is lined for up to $780m in milestone payments, as well as royalties on products that reach the market. ADCs have become a promising therapeutic modality in oncology and are one of the fastest-growing areas in cancer drug research. Chugai already has experience in ADCs, overseeing approvals of lymphoma treatment Polivy in Japan, a drug developed by its majority shareholder Roche. However, the pharma company currently does not list ADCs in development according to its drug pipeline . Araris, a spin-off from the Paul Scherrer Institute (PSI) and ETH Zurich, has developed linker technology that allows attachment of payloads to ‘off-the-shelf’ antibodies in a single step. The key differentiator of the biotech’s platform is it allows the conjugation of two or three cytotoxic payloads simultaneously. Araris claims its peptide linker technology overcomes limitations in current ADC technologies such as heterogeneity, aggregation in blood, and high costs. Araris CEO Dr Dragan Grabulovski told Pharmaceutical Technology : “A problem of current ADCs is that they carry and administer just one cytotoxic class, and this results in resistance and limited efficacy. Our technology allows these therapies to conjugate two or three or multi-warheads simultaneously. We call these multi-warhead ADCs and they mimic conventional chemotherapy.” Araris’ latest deal follows a transaction in 2023, which saw it enter an ADC collaboration agreement with Japan-based Taiho Pharmaceutical. According to Grabulovski, work with further pharma companies is on the cards: “We are continuing to talk to interested pharma…the goal is to enter into a few selected high-value partnerships.” Along with generating ADCs for partnered companies, Araris is also developing two internal programmes. One is against nectin-four, a target which already has an ADC at market courtesy of Pfizer’s Padcev (enfortumab vedotin), though Grabulovski says Araris’ candidate has three different payloads as a differentiating factor. The second programme is targeting NaPi2b, for which there is no approved ADC on the market. The ADC space has seen many billion-dollar deals as pharma companies look to shore up their pipeline with the emerging modality. Pfizer – who is also researching multi-payload ADCs, acquired Seagen for $43bn in December 2023 while MSD and AbbVie have also completed $10.8bn and $10.1bn deals in recent years.

License out/inADCAcquisitionDrug Approval

100 Deals associated with Swiss Federal Institute of Technology

100 Translational Medicine associated with Swiss Federal Institute of Technology

Corporation Tree

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 14 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Debio-1124 ( CCKB )	Respiratory Tract Neoplasms More	Phase 1
225Ac-PP-F11N ( CCKB )	Squamous Cell Carcinoma More	Preclinical
S-[11C]-Me-NB1 ( GluN2B )	Neurodegenerative Diseases More	Preclinical
[11C]MT107 ( CD80 )	Diagnostic agents More	Preclinical
R-[11C]-Me-NB1 ( GluN2B )	Neurodegenerative Diseases More	Preclinical

Deal

Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.